Note: This section contains information in English only.
Mon, 20 Jul 2026 09:30:06 GMT
Source: Dukascopy Bank SA
Novartis investors are focused on three upcoming H2 drug trials—pelacarsen, remibrutinib, and del-desiran—with $10 billion in peak sales potential. The results are vital to justifying the company's premium valuation amid looming patent expiries.
For further information regarding potential cooperation, please call us or make callback request.
To learn more about Dukascopy Bank Binary Options
/ Forex trading platform, SWFX and other trading related information, please call us or make callback request.
To learn more about Crypto Trading / CFD / Forex trading platform, SWFX and other trading related information, please call us or make callback request.
To learn more about Business Introducer and other trading related information, please call us or make callback request.
For further information regarding potential cooperation, please call us or make callback request.